Kaneka Completes Construction of Medical Device Plant in Hokkaido
30.8.2024 08:34:00 EEST | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido for the purpose of portfolio transformation and business expansion and held the opening ceremony on August 26. The Tomatoh Manufacturing Site is the seventh domestic business location*1 for the company and the first new one in 54 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829240050/en/
Tomatoh Manufacturing Site (Photo: Business Wire)
The medical device plant*2 completed at Tomatoh Manufacturing Site will produce adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™". The number of patients with arteriosclerosis obliterans (ASO)*3, which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. By securing the supply base through the new plant, we will dramatically expand our medical business to meet global demand.
The plant has achieved full automation of its production lines as a "smart factory" utilizing robot technology and plans to realize a "zero energy factory" that will reduce the primary energy consumption of the factory building to zero by using our photovoltaic modules, thereby promoting sustainable manufacturing.
In the future, Tomatoh Manufacturing Site will be actively utilized as a new production base for each business, as well as for further expansion of the medical business.
Based on our mission of "KANEKA thinks 'Wellness First'.", we will realize a world where advanced medical care is accessible to everyone and where science contributes to the innovation of the global environment and our daily lives. From Tomakomai, "Kaneka, the Dream Factory" will make this vision a reality.
Participants at the opening ceremony (From the left):
Yoshiro Aikawa, President of Taisei Corporation
Jun Kimura, Deputy Mayor of Tomakomai-city
Naomichi Suzuki, Governor of Hokkaido
Kimikazu Sugawara, Chairman of Kaneka Corporation
Kazuhiko Fujii, President of Kaneka Corporation
Shigenobu Sano, Senior Executive Director of Tomatoh Co., Ltd.
*1. Domestic business locations: Takasago Manufacturing Site, Osaka Manufacturing Site, Shiga Manufacturing Site, Kashima Manufacturing Site, Tomatoh Manufacturing Site, Tokyo Head Office, Osaka Head Office
*2. News Release January 23, 2022
Kaneka to Construct New Medical Device Plant in Hokkaido - Roughly 10 billion yen investment aimed at expanding global business -
https://www.kaneka.co.jp/en/topics/news/2022/ennr2201241.html
*3. A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia). In the early stages, it causes coldness, numbness, and gait disturbance. When the disease progresses to critical limb ischemia with pain and ulceration, the risk of leg amputation and death increases.
About Tomatoh Manufacturing Site
Company Name: Kaneka Corporation Tomatoh Manufacturing Site
Completed: August 26, 2024
Location: 6-253 Kashiwabara, Tomakomai-city, Hokkaido
Business Description: Production of medical devices
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829240050/en/
Contacts
KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
FPT Named in Forrester’s The SAP Services Landscape Report30.9.2026 06:00:00 EEST | Press release
Global technology corporation FPT has been included among the notable providers in The SAP Services Landscape, Q3 2026, published by Forrester Research, Inc. The report provides an overview of SAP services providers, examining their market focus, geographic presence, and business specializations to support enterprises in evaluating potential technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929359531/en/ The report includes FPT as a systems integrator with an Asia Pacific geographic focus and an industry focus spanning financial services and insurance, healthcare, and manufacturing. FPT identified SAP Business Data Cloud, SAP Enterprise Resource Planning (ERP), and SAP Supply Chain Management (SCM) as its three primary extended business scenario focus areas, what FPT believes reflects its emphasis on modernizing core enterprise systems and enabling more integrated, data-driven operations. Building on mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom